Bright Minds Biosciences (DRUG) Insider & Congress Trades

Smart money at a glance

Filings to Oct 24, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Mar 31, 2026: 1 added, 0 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about DRUG filings

Are insiders buying or selling Bright Minds Biosciences Inc (DRUG) stock?

Neither. Bright Minds Biosciences Inc (DRUG) insiders filed no open-market purchases or sales in the 90 days to Oct 24, 2026, according to SEC Form 4 filings.

Which members of Congress have traded DRUG recently?

None. No member of Congress disclosed a DRUG trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DRUG smart-money data?

This summary uses filings available on Oct 24, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Reported Aug 13, 2026

Earnings came in 87.8% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 13, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.17+87.77% beat

-$1.39 expected

Revenue

CAD 0.00

Financial statements: Alpha Vantage

Next report

What the street expects next

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Aug 13, 2026	-$0.17 / -$1.39Alpha Vantage	+87.77% beat	CAD 0.00 No estimate	Unavailable
Mar 31, 2026	May 20, 2026	-$1.09 / -$1.26Alpha Vantage	+13.49% beat	CAD 0.00 No estimate	Unavailable
Dec 31, 2025	Feb 12, 2026	-$0.97 / -$1.18Alpha Vantage	+17.80% beat	CAD 0.00 No estimate	Unavailable
Sep 30, 2025	Dec 23, 2025	-$0.57 / -$1.00Alpha Vantage	+42.86% beat	CAD 0.00 No estimate	Unavailable
Jun 30, 2025	Aug 14, 2025	-$0.74 / -$0.88Alpha Vantage	+15.91% beat	CAD 0.00 No estimate	Unavailable
Mar 31, 2025	May 15, 2025	-$0.29 / -$0.39Alpha Vantage	+25.64% beat	CAD 0.00 No estimate	Unavailable
Dec 31, 2024	Feb 13, 2025	$0.01 / -$0.50Alpha Vantage	+102.00% beat	CAD 0.00 No estimate	Unavailable
Sep 30, 2024	Nov 27, 2024	-$0.17 / -$0.60Alpha Vantage	+71.67% beat	CAD 0.00 No estimate	Unavailable

EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.

Smart money at a glance

Filings to Oct 24, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Mar 31, 2026: 1 added, 0 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about DRUG filings

Are insiders buying or selling Bright Minds Biosciences Inc (DRUG) stock?

Neither. Bright Minds Biosciences Inc (DRUG) insiders filed no open-market purchases or sales in the 90 days to Oct 24, 2026, according to SEC Form 4 filings.

Which members of Congress have traded DRUG recently?

None. No member of Congress disclosed a DRUG trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DRUG smart-money data?

Reported Aug 13, 2026

Earnings came in 87.8% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 13, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.17+87.77% beat

-$1.39 expected

Revenue

CAD 0.00

Financial statements: Alpha Vantage

Next report

What the street expects next

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Aug 13, 2026	-$0.17 / -$1.39Alpha Vantage	+87.77% beat	CAD 0.00 No estimate	Unavailable
Mar 31, 2026	May 20, 2026	-$1.09 / -$1.26Alpha Vantage	+13.49% beat	CAD 0.00 No estimate	Unavailable
Dec 31, 2025	Feb 12, 2026	-$0.97 / -$1.18Alpha Vantage	+17.80% beat	CAD 0.00 No estimate	Unavailable
Sep 30, 2025	Dec 23, 2025	-$0.57 / -$1.00Alpha Vantage	+42.86% beat	CAD 0.00 No estimate	Unavailable
Jun 30, 2025	Aug 14, 2025	-$0.74 / -$0.88Alpha Vantage	+15.91% beat	CAD 0.00 No estimate	Unavailable
Mar 31, 2025	May 15, 2025	-$0.29 / -$0.39Alpha Vantage	+25.64% beat	CAD 0.00 No estimate	Unavailable
Dec 31, 2024	Feb 13, 2025	$0.01 / -$0.50Alpha Vantage	+102.00% beat	CAD 0.00 No estimate	Unavailable
Sep 30, 2024	Nov 27, 2024	-$0.17 / -$0.60Alpha Vantage	+71.67% beat	CAD 0.00 No estimate	Unavailable

Bright Minds Biosciences Inc

Smart money at a glance

What do analysts expect?

Questions about DRUG filings

What funds are doing

What insiders are doing

How top traders are positioned

Earnings came in 87.8% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Bright Minds Biosciences Inc

Smart money at a glance

What do analysts expect?

Questions about DRUG filings

What funds are doing

What insiders are doing

How top traders are positioned

Earnings came in 87.8% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Bright Minds Biosciences Inc

Overview

Questions about DRUG filings

Smart money

Earnings

Financials

Technicals

Bright Minds Biosciences Inc

Overview

Questions about DRUG filings

Smart money

Earnings

Financials

Technicals